When to Expand to a New Continent in a Biotech Lifecycle

Most biotech tool companies ask the wrong question.

They ask: “How do we expand to Europe?”

The better question is: “When should we?”

Because expanding to a new continent too early doesn’t accelerate growth. It amplifies weakness. It spreads management bandwidth thinner. It makes distributors nervous. It exposes gaps in your positioning. And it burns cash at a rate that surprises even experienced founders.

Geographic expansion is not a growth strategy. It is a force multiplier. If the underlying machine is not working properly at home, multiplying it internationally just multiplies the problem.

Let’s start with when expansion actually makes sense.

1. After You Have Real Scientific Validation

Early preclinical data is exciting. Conference buzz is flattering. But neither pays salaries.

Expansion begins to make sense when:

• Your data is robust and reproducible

• Independent labs can generate similar results

• Your product is clearly associated with a defined experimental use case

• You can point to credible reference customers without hesitation

In life science tools, credibility is currency. Scientists don’t buy because you’re enthusiastic. They buy because your system helps them generate data that gets published or funded.

If you cannot articulate exactly what problem your product solves, for which type of lab, in which experimental context, then trying to expand to Europe or Asia won’t fix that for you.

Expansion works when your value proposition is already tight.

2. When Your Home Market Sales Engine Is Predictable

This is the uncomfortable one.

If your domestic sales are lumpy, personality-driven or dependent on founder relationships, you are not ready to expand. What you have is traction, not a system.

Before crossing continents, you should be able to answer:

• How long is your average sales cycle?

• Where do most leads originate?

• What percentage convert?

• What activities correlate with closed deals?

• What level of technical support is required pre- and post-sale?

If you don’t know the mechanics of your own machine, you can’t replicate it.

Expansion requires process. Not just optimism.

3. When Distributor-Only Coverage Has Plateaued

Distributors are useful. They open doors, localise language, reduce fixed cost risk and create early reach. But they optimise for their own incentives, not yours.

Distributor-only coverage often plateaus for three predictable reasons:

• Complex products require deeper technical engagement than a distributor rep can provide

• Your product is one of twenty lines they carry

• You don’t control the data, pipeline or customer relationship

At some point, you realise revenue isn’t growing in proportion to market size. The issue is not demand. It is control.

That’s when expansion becomes strategic rather than aspirational.

A direct presence does not replace distributors immediately. But it changes the centre of gravity. You move from being “one of their suppliers” to building your own long-term market position.

4. When Management Bandwidth Exists

Opening a remote office sounds simple. It is not.

Even a one-person outpost creates complexity:

• Legal structure

• Banking

• Employment compliance

• Tax exposure

• Pricing alignment

• Inventory decisions

• Support expectations

• Cultural nuance

And then there is management.

If your leadership team is already stretched, expansion will not energise them. It will exhaust them.

Continental expansion only works when someone at senior level owns it properly. Not as a side project. Not as “something we’ll keep an eye on.”

Ownership matters. Otherwise the remote office becomes a lonely experiment with unrealistic targets and declining morale.

5. When You Understand Who You Are Targeting

Geography does not replace segmentation.

If you cannot clearly define your ideal customer at home, adding another continent just multiplies ambiguity.

Be precise:

• What type of lab?

• What model organism?

• What grant size?

• What technical bottleneck are you solving?

If you can’t answer those cleanly, expansion is premature.

In fact, international expansion can be useful as a stress test. It exposes whether your positioning is robust or fuzzy. But that only works if you are honest about what you see.

Now let’s talk about when not to expand.

When Expansion Is a Mistake

1. When the Product Isn’t Established at Home

If adoption is slow domestically, fix that first.

International markets are not testing grounds for unfinished positioning. They are harsher environments with longer feedback loops and higher cost of correction.

You don’t solve a weak value proposition by changing geography.

2. When You’re Still “Discovering” the Customer

If your internal conversations include phrases like:

• “We’re still figuring out who this is really for.”

• “There are loads of applications.”

• “It’s disruptive, so it’s hard to define.”

Then you are not ready.

Ambiguity is expensive in your home market. Internationally, it becomes lethal.

3. When Cash Flow Is Fragile

International expansion delays revenue before it accelerates it.

Hiring locally, travelling frequently, adapting pricing, supporting distant customers and potentially carrying local costs all stretch working capital.

If your business is already sensitive to short-term cash swings, geographic expansion will amplify that stress.

Growth funded by hope is not growth. It is risk.

---

The Real Question

Expansion is rarely about geography.

It is about control.

Control of:

• Customer data

• Pipeline visibility

• Technical messaging

• Pricing discipline

• Long-term brand positioning

Distributors give reach. Direct presence gives control.

The decision to expand continents should therefore be framed less as “Can we sell there?” and more as “Is it time to take control there?”

That moment usually comes when:

• You have proven product-market fit at home

• You understand your sales mechanics

• Distributor growth has flattened

• Management can absorb complexity

• Cash flow can tolerate delayed payoff

Do it earlier and you dilute focus.

Do it later and you leave long-term market ownership in someone else’s hands.

The decision tree

There is no perfect timing. But there is clearly premature timing.

Most biotech tool companies don’t fail internationally because the market wasn’t there. They fail because they expanded before they were operationally ready to carry the weight.

Expanding to a new continent is not a badge of ambition.

It is a test of maturity.

Pass that test first at home. Then cross the ocean.

Rory Geoghegan

24th of February 2026

Replacing guesswork with processwork!